Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 6,767 matching trials from the live ClinicalTrials.gov search.
Filters: Bethesda, Maryland Clear all
Completed Phase 2Phase 3 Interventional Results available

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

NCT00146328
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
86
States / cities
Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Phase 1 Interventional

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

NCT06257693
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
enzalutamide
Drug
Lead sponsor
Alessa Therapeutics Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Fresno, California • San Francisco, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

NCT00064714
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 27, 2026, 2:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT01658904
View directory record Official record
Conditions
Multiple Myeloma, Leukemia, Plasma Cell
Interventions
Carfilzomib, Melphalan, Filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 27, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional

Ublituximab + Ibrutinib in Select B-cell Malignancies

NCT02013128
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Ublituximab, Ibrutinib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
18
States / cities
Huntsville, Alabama • Tucson, Arizona • Santa Barbara, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss

NCT07627971
View directory record Official record
Conditions
GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
Interventions
SKY-GJB2
Combination Product
Lead sponsor
Skylark Bio Inc.
Industry
Eligibility
9 Months to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716
View directory record Official record
Conditions
B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter Transformation
Interventions
Tacabrutideg
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Completed No phase listed Observational

Efficacy of Elevated CD4 Counts on CMV Retinitis

NCT00091884
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of Estrogen for Postpartum Depression

NCT00059228
View directory record Official record
Conditions
Postpartum Depression, Depression
Interventions
17beta Estradiol, Placebos
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
20 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting No phase listed Observational

Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry

NCT03231644
View directory record Official record
Conditions
Fibrous Dysplasia, McCune Albright Syndrome, Mazabraud Syndrome
Interventions
Not listed
Lead sponsor
Tovah Burstein
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 27, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

NCT03151304
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Pracinostat, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Duarte, California • San Diego, California • Augusta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 27, 2026, 2:12 PM EDT
Completed No phase listed Observational

Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0

NCT02290392
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
30 Years to 55 Years
Enrollment
1,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

NCT02054104
View directory record Official record
Conditions
Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura, Sarcoma, Melanoma
Interventions
H1299 cell lysates, Cyclophosphamide, Celecoxib, Iscomatrix adjuvant
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 27, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)

NCT00001781
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CGP 77116
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 2:12 PM EDT
Completed No phase listed Observational

The Treatment and Natural History of Acromegaly

NCT00001981
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Deep Brain Stimulation management
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Completed No phase listed Observational

Follow-Up Study of People Treated for Scoliosis

NCT02546479
View directory record Official record
Conditions
Breast and Other Cancer Incidence and Mortality, All Cause Mortality, Circulatory Disease Mortality, Respiratory Disease Mortality
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 95 Years · Female only
Enrollment
5,573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 27, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Interventions
Patritumab Deruxtecan, Platinum-based chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Leptin to Treat Lipodystrophy

NCT00005905
View directory record Official record
Conditions
Lipodystrophy
Interventions
hu Leptin (A-100)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 27, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Evaluating Patient Participation in Phase I Clinical Trials

NCT00043030
View directory record Official record
Conditions
Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 27, 2026, 2:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Molecular Anatomy of Oral Wound Healing

NCT01078467
View directory record Official record
Conditions
Wounds and Injuries, Wound Healing, Ulcer
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 40 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT03708900
View directory record Official record
Conditions
Cushing Syndrome
Interventions
LCI699
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Completed No phase listed Observational

Evaluation and Diagnosis of People With Pain and Fatigue Syndromes

NCT00677157
View directory record Official record
Conditions
Fatigue
Interventions
Not listed
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 27, 2026, 2:12 PM EDT